372 related articles for article (PubMed ID: 31229353)
1. Towards Immunotherapy for Pediatric Brain Tumors.
Wang SS; Bandopadhayay P; Jenkins MR
Trends Immunol; 2019 Aug; 40(8):748-761. PubMed ID: 31229353
[TBL] [Abstract][Full Text] [Related]
2. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy.
Wu WT; Lin WY; Chen YW; Lin CF; Wang HH; Wu SH; Lee YY
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673696
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma Therapy in the Age of Molecular Medicine.
Geraldo LHM; Garcia C; da Fonseca ACC; Dubois LGF; de Sampaio E Spohr TCL; Matias D; de Camargo Magalhães ES; do Amaral RF; da Rosa BG; Grimaldi I; Leser FS; Janeiro JM; Macharia L; Wanjiru C; Pereira CM; Moura-Neto V; Freitas C; Lima FRS
Trends Cancer; 2019 Jan; 5(1):46-65. PubMed ID: 30616755
[TBL] [Abstract][Full Text] [Related]
4. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
Plant-Fox AS; O'Halloran K; Goldman S
Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
[TBL] [Abstract][Full Text] [Related]
5. T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.
Kwok D; Okada H
J Neurooncol; 2020 Apr; 147(2):281-295. PubMed ID: 32185647
[TBL] [Abstract][Full Text] [Related]
6. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy in brain tumors].
De Carli E; Delion M; Rousseau A
Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
[TBL] [Abstract][Full Text] [Related]
8. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.
Sengupta S; Mao G; Gokaslan ZS; Sampath P
Cancer Gene Ther; 2017 Mar; 24(3):121-129. PubMed ID: 27767090
[TBL] [Abstract][Full Text] [Related]
10. Applications and current challenges of chimeric antigen receptor T cells in treating high-grade gliomas in adult and pediatric populations.
Jovanovich N; Habib A; Hameed NF; Edwards L; Zinn PO
Immunotherapy; 2023 Apr; 15(5):383-396. PubMed ID: 36876438
[TBL] [Abstract][Full Text] [Related]
11. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
Chuntova P; Downey KM; Hegde B; Almeida ND; Okada H
Front Immunol; 2018; 9():3062. PubMed ID: 30740109
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of Primary Brain Tumors: Facts and Hopes.
Buerki RA; Chheda ZS; Okada H
Clin Cancer Res; 2018 Nov; 24(21):5198-5205. PubMed ID: 29871908
[TBL] [Abstract][Full Text] [Related]
13. The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors.
Del Baldo G; Del Bufalo F; Pinacchio C; Carai A; Quintarelli C; De Angelis B; Merli P; Cacchione A; Locatelli F; Mastronuzzi A
Front Immunol; 2023; 14():1142597. PubMed ID: 37025994
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
Choi BD; Curry WT; Carter BS; Maus MV
Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
[TBL] [Abstract][Full Text] [Related]
15. Cancer immune therapy for lymphoid malignancies: recent advances.
Klausen U; Jørgensen NGD; Grauslund JH; Holmström MO; Andersen MH
Semin Immunopathol; 2019 Jan; 41(1):111-124. PubMed ID: 30006739
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy approaches for the treatment of diffuse midline gliomas.
Bernstock JD; Hoffman SE; Kappel AD; Valdes PA; Essayed W; Klinger NV; Kang KD; Totsch SK; Olsen HE; Schlappi CW; Filipski K; Gessler FA; Baird L; Filbin MG; Hashizume R; Becher OJ; Friedman GK
Oncoimmunology; 2022; 11(1):2124058. PubMed ID: 36185807
[TBL] [Abstract][Full Text] [Related]
17. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
18. Cellular immunity and immunotherapy of brain tumors.
Prins RM; Liau LM
Front Biosci; 2004 Sep; 9():3124-36. PubMed ID: 15353342
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
20. Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and -γ.
Chandrasekaran S; Funk CR; Kleber T; Paulos CM; Shanmugam M; Waller EK
Front Immunol; 2021; 12():718621. PubMed ID: 34512641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
